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ABSTRACT OF DISSERTATION 
CROSS-VALIDATION OF THE VALIDITY-10 SUBSCALE OF THE 
NEUROBEHAVIORAL SYMPTOM INVENTORY  
The present study is a cross-validation of the Validity-10 embedded symptom 
validity indicator from the Neurobehavioral Symptom Inventory (NSI) for the detection 
of questionable response validity during evaluation for mild traumatic brain injury (TBI). 
The sample and data derived from a three-site Veterans Affairs (VA) parent study 
to validate the TBI Clinical Reminder, a routine set of questions asked of all recently 
returned veterans at VA facilities to screen for history of TBI. In the parent study, 
veterans recently returned from Iraq and Afghanistan underwent an evaluation for TBI 
with a physician and completed an assessment battery including neuropsychological tests 
of cognitive performance and indicators of symptom and performance validity, 
psychiatric assessment measures, a structured interview for post-traumatic stress disorder 
(PTSD), and various behavioral health questionnaires. The present study estimated the 
test operating characteristics of Validity-10, using NSI results gathered during the 
physician evaluation to compute Validity-10 scores, and using results on several other 
measures of symptom and performance validity from the assessment battery as criteria 
for questionable response validity. Only individuals who had positive screen results for 
TBI on the TBI Clinical Reminder prior to full evaluation were included in the present 
sample. 
Sensitivity of Validity-10 to questionable validity was moderately high (.60 - .70) 
to excellent (.90 - 1.00) at high levels of specificity (> .80). Effects of different base rates 
of and different criteria for questionable validity on the utility of Validity-10 were 
explored as well. Chi-square analyses to determine the effect of PTSD symptoms on the 
utility of Validity-10 demonstrated overall classification accuracy in general, and false 
positive rate in particular, were relatively poorer when used with individuals who 
reported significant PTSD symptoms. Overall, these findings support the use of Validity-
10 (at cut score Validity-10 ≥ 19) to identify those veterans being evaluation for mild TBI 
in the VA system who should be referred for comprehensive secondary evaluation by a 
clinical neuropsychologist using multiple forms of symptom and performance validity 
testing. Further studies of the effects of PTSD symptoms on the accuracy of Validity-10 
for this purpose are recommended. 
KEYWORDS: Neuropsychological Assessment, Traumatic Brain Injury, Validity 
Testing, Neurobehavioral Symptom Inventory, Veterans 
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Chapter 1—Introduction 
This dissertation describes the cross-validation of an embedded symptom validity 
subscale of the Neurobehavioral Symptom Inventory (NSI; Cicerone and Kalmar, 1995). 
The present introduction outlines the structure of the document and presents the basic 
argument justifying the study in brief.  Each point is further explained and supported in 
the literature review below. The methods section describes the provenance of the data 
analyzed, the instruments and scores used for measurement, and the analytic procedure 
used to answer the research questions. The results section presents the results of the 
analyses interpreted in answer to the research questions. Finally, the discussion section 
relates the study findings to the broader literature and current clinical practices, presents 
limitations of the present study and methodological issues pertinent to the area of study, 
and summarizes primary conclusions drawn from the study. 
Numerous veterans seek treatment through the United States Veterans Health 
Administration (VHA), and the wars of the past two decades have increased the numbers 
of veterans seeking evaluation for traumatic brain injury (TBI). Indeed, because of its 
high prevalence among returning veterans, TBI has been called the “signature injury” of 
the Operation Iraqi Freedom and Operation Enduring Freedom (OIF/OEF) conflicts in 
Iraq and Afghanistan (Taneilian and Jaycox, 2008). VHA has instituted a screening 
process for TBI to facilitate the appropriate referral of veterans such that all individuals at 
risk for TBI are examined by a physician first and that those in need of further assessment 
are evaluated by a comprehensive team including a clinical neuropsychologist. Three 
major complications threaten appropriate diagnosis and referral in this context. First, the 
vast majority of TBIs experienced in civilian life and combat are of mild severity, and the 
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diagnosis of mild TBI relies a great deal on the presence of symptoms that are often 
vague, nonspecific, or unverifiable. Second, the validity of symptom reporting and 
performance on neuropsychological measures is known to be more questionable in the 
presence of the possibility of secondary gain. That is, in settings wherein financial or 
other external incentives to feign or exaggerate symptoms of mild TBI are present, the 
base rate of feigning and exaggeration rises. Evaluation within VHA is clearly such a 
setting, because veterans are often awarded disability compensation if evaluators 
conclude that a given disability is “service-connected”—that it exists due to combat 
experience. Third, as combat veterans, most of those evaluated by VHA for mild TBI are 
at risk for posttraumatic stress disorder (PTSD) due to combat stress. PTSD, 
unfortunately, shares many of the vague, nonspecific, and often unverifiable symptoms 
associated with mild TBI.  
Considering these three complications, it would be desirable for VHA to have an 
objective indicator of questionable validity of symptom presentation for mild TBI, and it 
would as well be desirable to know how the operating characteristics of that indicator are 
affected by the presence of combat PTSD. Moreover, it would be ideal to have this 
indicator available at the time of TBI evaluation by the physician, so that individuals with 
an indicator of questionable validity may be referred for further evaluation by the clinical 
neuropsychologist rather than be referred to TBI support services or to receive 
compensation based on self-reported information alone. Researchers have recently 
identified that one measure administered during all VHA medical TBI evaluations, the 
Neurobehavioral Symptom Inventory (NSI), contains items that have potential for use as 
an embedded validity scale. Preliminary work has found this scale, dubbed “Validity-10,” 
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to be useful for classifying test-taker responses as valid or invalid. The present 
dissertation replicates these findings in an independent sample of veterans using multiple 
symptom validity and performance validity tests as criterion measures. 
4 
Chapter 2—Literature Review 
Mild Traumatic Brain Injury  
Traumatic brain injury (TBI) is damage to the tissue of the brain due to blunt 
force trauma or violent rotational forces.  The presentation and course of TBI varies by 
severity of the injury.  Severity of TBI is diagnosed based on the length of loss of 
consciousness; the duration of a delirium-like state of confusion called post-traumatic 
amnesia (PTA); and impairment of ocular, motor, and vocal responsiveness, often 
assessed using the Glasgow Coma Scale (Teasdale & Jennett, 1974).  Recommended 
rules for classifying TBI severity according to these measures vary across organizations, 
though many are similar in practice.  Table 1 presents a typical classification system, 
developed by the World Health Organization Collaborating Centre Task Force of Mild 
Traumatic Brain Injury and endorsed by the National Academy of Neuropsychology 
(Ruff et al., 2009).  Moderate or severe TBI typically results in loss of consciousness 
followed by a period of retrograde and anterograde PTA, which may resolve, leaving 
residual deficits in cognitive function.  Severe TBI may result in protracted coma or 
death, longer duration of PTA, and more pronounced disability. 
Emergency departments in the United States see roughly 1.1 million visits for TBI 
annually, only 15% of which fall in the moderate to severe range (Corrigan, Selassie, and 
Orman, 2010).  The remaining majority would be considered mild TBIs (mTBIs), 
wherein there is little to no loss of consciousness or PTA.  Moreover, an unknown 
number of mTBIs are never evaluated or treated.  It is common practice to differentiate 
between mild and “complicated mild” TBI, the latter of which applies when there is 
detectable injury on emergency CT imaging (Williams, Levin, and Eisenberg, 1990).  
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The distinction is useful because complicated mild TBIs are more similar in course to 
moderate TBI than to mild TBI. Often, complicated mild TBIs are excluded from 
research studies. Certain organizations, such as the U.S. Departments of Defense (DoD) 
and Veterans Affairs (VA), prefer to classify such injuries as moderate because of that 
similarity (Department of Veterans Affairs and Department of Defense, 2009).  In all 
other respects, the VA/DoD guidelines for TBI severity are virtually identical to those 
presented in Table 2.1. 
Neuropathological studies identify traumatic axonal injury, including stretching, 
swelling, and degeneration, as the primary structural determinant of brain damage 
severity in mTBI (see Biasca & Maxwell, 2007; Bigler & Maxwell, 2011; Saatman, 
Serbst, & Burkhardt, 2009).  Processing speed, attention, and memory are the cognitive 
domains most typically affected, but the symptom picture varies by etiology and the locus 
of any focal injury.  The course of mTBI is a subject of debate among brain injury 
researchers and clinicians.  Whereas it is clear that moderate to severe TBI often results 
in permanent cognitive impairment, the long-term cognitive sequelae of mTBI are less 
easily characterized.  It is well established that the majority of individuals who report 
mTBI symptoms return to baseline cognitive function within months post-injury (Levin 
et al., 1987).  Meta-analytic studies of the overall impact of mTBI on neuropsychological 
function have found that initial cognitive impairment may be pronounced—about one 
standard deviation below expectation—but, on average, resolves to minimal effect sizes 
after about one week, further improving over the following 3-6 months (Belanger & 
Vanderploeg, 2005; Broglio & Puetz, 2008; Karr, Areshenkoff, and Garcia-Barrera, 
2014; Schretlen & Shapiro, 2003). 
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It is also well recognized that a small minority of individuals report symptoms, 
produce impaired scores on neuropsychological testing, and have poor psychosocial 
outcomes long after their mTBI sequelae would be expected to have resolved (Kay, 
Newman, & Cavallo, 1997).  Reported symptoms may include headaches, dizziness, 
malaise, fatigue, noise intolerance, mood disturbance, difficulty with memory or 
concentration, insomnia, alcohol intolerance, apathy, or social inappropriateness 
(Cicerone & Kalmar, 1995).  Both the WHO and the American Psychiatric Association 
have proposed research criteria for a postconcussional syndrome/disorder (PCS), but the 
designation has not been widely adopted for several reasons.  Healthy adults meet PCS 
criteria at rates similar to those with a history of mTBI (Iverson & Lange, 2003).  
Moreover, high rates of PCS symptoms are associated with outpatient psychological 
treatment, outpatient medical treatment, personal injury litigation, orthopedic injury, 
chronic pain, and posttraumatic stress disorder.  
Some researchers are satisfied that there are no lasting cognitive effects of mTBI.  
On this view, the differences found after 6 months in the small minority of cases noted 
above are attributable to situational factors, such as motivation level and testing 
conditions, and are not due to injury to brain tissue.  One meta-analytic study found that 
residual effects of mTBI on neuropsychological testing were very small in research 
samples, whereas effects in clinical and forensic samples were large (Belanger et al., 
2005).  Meta-analysis also revealed that persistent differences in neuropsychological test 
scores after mTBI have an effect size of g = -0.07, which translates to a negligible clinical 
difference (Rohling et al., 2011).  Others have argued that there may indeed be credible 
cognitive sequelae of mTBI that persist well outside the normal range.  On this view, the 
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group mean differences reported in studies of mTBI course apply to the majority of the 
group and are largely unaffected by the performance of the small minority with persistent 
damage to the brain, which is a low base rate condition (Pertab, James, & Bigler, 2009; 
Iverson, 2010; but see Rohling, Larrabee, and Millis, 2012, for a rebuttal of the 
methodological argument and Bigler et al., 2013, for further discussion).  Bigler & 
Maxwell (2011) reviewed mounting evidence from neuroscience and neuroimaging 
studies that there is indeed altered brain function in some persons with mTBI, including 
changes in various biomarkers of structural damage, inflammatory response, evidence of 
traumatic injury detectable with specialized imaging techniques, neuropathologic 
differences on autopsy after mTBI, and in vivo changes in neurotransmitter levels.  
Iverson (2012) reviewed evidence that factors such as resilience, multiple bouts of 
depression, other psychiatric illness, and poor social adjustment have reciprocal 
relationships with cognitive function, and he proposed a biopsychosocial model of 
outcome from mTBI.  Neuropsychological studies continue to emerge that either find or 
fail to find late cognitive effects of mTBI, and there is no clear consensus regarding the 
possibility of persistent cognitive sequelae of mTBI, especially under stressful conditions. 
Combat TBI. War presents numerous opportunities for injury to the head and 
brain, including projectile trauma, falls, hand-to-hand assaults, and exposure to 
concussive blasts from explosive devices.  With the abundance of improvised explosive 
devices (IEDs) in the Iraq and Afghanistan wars, blast exposure has gained research 
attention as a cause of injury.  As in the general population, mTBIs represent most TBIs 
experienced by soldiers in combat.  The U.S. Department of Defense (U.S. DoD; 2012) 
reported that from the year 2000 to November 2012, just over 262,000 members (11.3%) 
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of the U.S. Armed Forces were given medical diagnoses of TBI, over three-fourths of 
which were acquired during active duty.  Mild TBI accounted for 76.4% of these 
diagnoses.  These DoD figures and others based on real-time surveillance of reported 
events fall below estimates based on post-deployment assessment, which range from 
11.2% to 22.8% (Mental Health Advisory Team V, 2008; Schwab et al., 2007; Tanielian 
& Jaycox, 2008; Hoge et al., 2008; Schneiderman, 2008; Terrio et al., 2009). 
Both mid-deployment and post-deployment estimates face methodological 
challenges: in-theater assessment personnel may be relatively untrained or under stress; 
the in-theater assessment setting may be suboptimal; post-deployment assessments are 
often designed for screening purposes, allowing for many false positives; post-
deployment assessment introduces the fallibility of retrospective report; and situational 
incentives to distort one’s presentation abound, such as a desire to remain of use or to 
escape danger, the potential to collect disability benefits, or mistrust of the uses to which 
one’s health information may be put.  The DoD and VA both screen returning veterans 
for possible TBI and refer those who with a positive result for more thorough assessment 
and, where appropriate, rehabilitation services.  Given the difficulties in assessing 
presence and outcome of mTBI in veterans, research support for unique effects of mTBI 
are scant for this population, and much of current research and clinical work applies 
knowledge gained from civilian populations to this unique group. 
Test Validity 
Given the presence of numerous incentives to distort one’s responses to 
psychological measures, it is important to be able to identify whether the results of a 
given evaluation are valid for interpretation. To accomplish this task, psychologists have 
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developed validity tests that are sensitive to response distortion and relatively insensitive 
to clinical conditions. Instruments developed to detect response distortion on self-report 
measures of symptoms are called “symptom validity tests” (SVTs), and those designed to 
detect response distortion on performance-based tests of ability are called “performance 
validity tests” (PVTs; Larrabee, 2012). A further distinction is drawn between validity 
tests that are embedded within other clinical measures (“embedded validity tests”) and 
those that are administered with the single dedicated purpose of assessing response 
validity (“standalone validity tests”; Berry and Schipper, 2008; Rogers, 2008a). The 
various forms of response distortion include providing random responses, minimization 
of problems (“faking good”) and feigning or exaggeration of problems (“faking bad”; 
Rogers, 2008c).  
Strategies for detecting faking bad generally involve either identification of 
unlikely presentations or identification of excessive impairment (Rogers, 2008b). An 
unlikely presentation may be identified through examination of the magnitude of errors, 
the discordance of errors with item difficulty, the discordance of errors with known 
learning principles (e.g. recognition memory scores lower than free recall scores), or the 
pattern of scores across cognitive measures with reference to expected patterns of 
impairment. Strategies to detect excessive impairment focus instead on the extent of 
impairment rather than on the qualitative nature of impairment. These strategies include 
identification of deficits on tasks measuring cognitive functions that tend to be preserved 
in neurological impairment; performance significantly below chance expectations; or 
deficient performance as compared with that of samples of individuals with neurological 
disorders and no identified incentive to feign. 
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SVTs and PVTs are ideally submitted to two complementary forms of validation 
study, the simulation design and the known-groups design (Berry and Schipper, 2008; 
Rogers 2008c). The simulation design is an analogue study comparing honestly-
responding individuals who have clinical conditions to individuals without clinical 
conditions who have been instructed and incentivized to feign or exaggerate symptoms. It 
has the benefit of high internal validity, such that variability in outcomes may be 
attributed to experimental manipulation of factors such as instructions, coaching, and 
incentives. The simulation design has relatively weak external validity, in that results 
may not be generalizable to the analogized real-world situations. The known-groups 
design classifies real-world individuals into groups according to criterion evidence of 
malingering and compares the performance of those unlikely to be malingering to those 
likely to be malingering. The known-groups design has the benefit of high external 
validity, in that its results are drawn from a real-world context and are likely to 
generalize. Internal validity is relatively weak because the investigator has little ability to 
manipulate variables, which complicates inferences of causation. Tests that exhibit 
satisfactory operating characteristics under both paradigms benefit from the strengths of 
each whereas weaknesses are mitigated. 
Test operating characteristics are summarized with various indices of diagnostic 
classification accuracy. Suppose there is a study population, some portion of which has a 
condition of interest. That proportion is the base rate (BR) of the condition in that 
population. Further suppose that there is a test for the condition of interest that assigns a 
positive or negative test sign to each individual depending on whether that person 
produced a score above or below a given cut score. To summarize the classification 
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accuracy of the test using that cut score, one may calculate hit rate, sensitivity, 
specificity, positive and negative predictive values, as follows. Sensitivity is the 
proportion of those with the condition who received a positive test sign. Specificity is the 
proportion of those without the condition who received a negative test sign. Sensitivity 
and specificity are intrinsic to the use of a test at a particular cut score in a particular 
population; they do not vary with changes in the base rate of the condition. The predictive 
values supply converse indices of classification accuracy that take into account the base 
rate and answer the pressing clinical question: “Given that a person produces a particular 
test sign, what is the probability that the person has or does not have the condition?” 
Specifically, the positive predictive value (PPV) is the proportion of individuals with a 
positive test sign who do have the condition; the negative predictive value (NPV) is the 
proportion of individuals with a negative test sign in which the condition is absent. Like 
sensitivity, specificity, and hit rate, the predictive values depend upon the particular test, 
the particular cut score, and the particular population; unlike the others, predictive values 
vary with changes in the base rate. 
Posttraumatic Stress Disorder  
Posttraumatic stress disorder (PTSD) is a syndrome of persistent, impairing 
symptoms following psychological trauma involving the threat or occurrence of injury, 
death, or loss of physical integrity to the individual or to someone close to the individual 
(American Psychiatric Association, 2013). Persistent symptoms involve (a) 
reexperiencing of the traumatic incident, such as flashback memories, recurrent dreams, 
or intense psychological or physiological reaction to reminders of the event; (b) 
avoidance of reminders of the incident, such as thoughts, feelings, conversations, people, 
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or places, inability to recall important aspects of the event, or emotional numbness, such 
as decreased ability to feel emotions like love, happiness, or connection with others, or a 
sense that one’s future will be cut short; and (c) hyperarousal, such as an inability to fall 
or stay asleep, increased startle response, hypervigilance to threat, irritability, outbursts of 
anger, or difficulty concentrating.  Occurrence of the syndrome within 30 days of the 
event is considered an acute stress disorder (ASD), and an ASD that persists beyond 30 
days after the event is revised to a diagnosis of PTSD.  Moreover, symptoms must cause 
significant impairment in social or work functioning, or in other important domains of 
function.  PTSD may be specified as “chronic” if symptoms persist from more than 6 
months post-trauma or as “delayed onset” if symptoms first arise more than one month 
post-trauma.  Lifetime prevalence of PTSD was estimated at 7.8% in the National 
Comorbidity Survey, with two-thirds of diagnoses eventually remitting (Kessler et al., 
1995). 
Most symptoms listed in the diagnostic criteria for PTSD are affective or 
behavioral, but the mention of difficulty concentrating is a recognition of cognitive 
complaints among those with the disorder.  Indeed, meta-analysis has revealed that 
combat veterans with PTSD tend to perform worse than combat veterans without PTSD 
on neuropsychological tests of verbal and visual memory, with medium to large effect 
sizes (Johnsen & Asbjornsen, 2008; Brewin, Kleiner, Vasterling, & Field, 2007).  
Individual studies have found similar effects on measures of executive functions (Hart et 
al, 2008; Jenkins et al., 2000; Beckham et al., 1998).  Methodological strength is variable 
across studies, and the presence of such confounding factors as IQ, substance use 
disorders, and incentive to overreport was rarely addressed in early studies.  Recent 
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studies that controlled or screened for differences on these factors replicated the expected 
neuropsychological differences (Geuze, Vermetten, de Kloet, Hijman, & Westenberg, 
2009; Samuelson et al., 2006), as did the examination by Shandera-Ochsner et al. (2013) 
of a single-site subsample of the multi-site VA study sample to be examined in the 
current project. 
Combat PTSD. Magruder et al. (2004) used a telephone-administered structured 
interview to estimate the prevalence of PTSD at 10% among veterans known to the VA 
medical system.  Hoge et al. (2004; 2007) reported a slightly higher range, from 13-17% 
among veterans.  The traumatic events that meet Criterion A of the DSM-5 diagnosis 
include prolonged exposure to threat of death in a combat zone, injury to the individual, 
and witnessed injury or death of other soldiers or civilians, among others.  Assessment of 
combat-related PTSD is complicated by possible delayed onset of symptoms; adjustment 
to a stark change of environment and demands from a combat zone to home, including 
available social support and norms for social interaction; lack of prior information 
regarding premorbid functioning, psychiatric and otherwise; the time demand involved in 
making a systematic assessment of onset and severity of a wide range of symptoms; the 
need for clinical judgment in determining whether a given symptom is connected to the 
traumatic event; and a context of assessment that may incentivize over- or under-
reporting of symptoms, as described above regarding mTBI diagnosis.  Also like mTBI, 
the military and VA screen all returning veterans for PTSD symptoms, make referrals for 
more focused assessment, and provide or refer the veteran to appropriate services, 
including well validated interventions such as Prolonged Exposure Therapy (Foa, 
Hembree, & Rothbaum, 2007) and Cognitive Processing Therapy (Resick et al., 2006). 
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Mild TBI and Combat PTSD  
Carlson et al. (2011) performed a systematic review of evidence regarding 
prevalence estimates, diagnostic accuracy, and treatment approaches for mTBI and PTSD 
in combination.  The studies examined varied widely in specific aims and study design, 
etiology of trauma, sample size, and measures employed.  Only 9 of the 38 studies that 
met criteria for inclusion examined U.S. military samples.  Prevalence estimates for 
comorbid mTBI and PTSD were highly variable across studies, but three large-scale 
studies of OIF/OEF veterans estimated the prevalence of probable comorbidity at 5-7% 
(Hoge et al., 2008; Schneiderman et al., 2008; Tanielian & Jaycox, 2008).  For veterans 
with probable mTBI, the estimated prevalence of comorbid PTSD ranged from 33-39%.  
Current Practice and Research  
The Veterans Health Administration (VHA) continues to evaluate numerous 
OIF/OEF veterans each year for traumatic brain injury. The need to include symptom 
validity testing and performance validity testing in evaluations for mTBI is well 
established, both in civilian and veteran populations. As noted earlier, VHA policy is to 
ask every returning veteran a set of questions (the TBI Clinical Reminder) to screen the 
individual for possible TBI history and refer those with positive results to further 
evaluation by a TBI physician (the Comprehensive TBI Evaluation, or CTE). The CTE 
includes a physical examination, interview, and completion of self-report symptom 
measures, including the NSI. The CTE physician evaluates the likelihood of brain injury 
involvement, and if TBI is likely, the individual is referred for a secondary TBI 
evaluation, which includes neuropsychological assessment. The neuropsychological 
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evaluation is the first context in which the validity of the individual’s symptom report and 
behavioral performance is formally evaluated.  
It would be beneficial to have a formal test of invalid responding “upstream” from 
the neuropsychological evaluation because such a test would provide symptom validity 
information gathered at a different time point, in a different context, and by a different 
clinician than the bulk of the test data available to the neuropsychologist. Thus, the 
neuropsychologist, who is the clinician best equipped to interpret symptom validity test 
data in the context of other test data, would have the benefit of repeated observation, 
varied setting, and varied tester when making the final judgment as to symptom and 
performance validity. Should the NSI, which is completed as part of the CTE before 
neuropsychological evaluation, yield a valid and useful measure of symptom validity, the 
VHA need not change procedure except to refer individuals with positive test signs on the 
measure embedded in the NSI for neuropsychological evaluation. Hence, recent research 
has focused on identifying embedded measures of symptom validity within the NSI 
(Lange et al., 2013b; Vanderploeg et al., 2014; Lange et al., 2015, 2016).  
Lange et al. (2013b) first developed a five-item measure called the Mild Brain 
Injury Atypical Symptoms Scale (mBIAS) for use in conjunction with the NSI and the 
PTSD Checklist—Civilian (PCL-C) to detect symptom feigning among veterans being 
evaluated for postconcussional disorder (PCD) and PTSD. This initial simulation study 
employed a sample of 85 Australian undergraduate students assigned to perform honestly 
(n = 24), feign PCD (n = 29), or feign PTSD (n = 32). The group identified cutoff scores 
for “probable exaggeration” (mBIAS score ≥ 8), which had a low sensitivity of .34 and 
excellent specificity of 1.0, and for “possible exaggeration” (mBIAS ≥ 6), which had 
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good sensitivity of .74 and good specificity of .88. They recommended further study of 
the mBIAS using veteran clinical samples. 
Vanderploeg et al. (2014) identified NSI items to form a subscale for clinically 
atypical or bizarre symptoms (NIM5), a subscale of items endorsed with very low 
frequency (LOW6), and a combined scale of non-overlapping items in NIM5 and LOW6 
(Validity-10). Three clinical samples were used to identify items for the scales: a sample 
of consecutive referrals to an outpatient military brain injury clinic (N = 443), all VHA 
patients who had completed the CTE and showed evidence of brain injury (N = 36,655), 
and respondents to a Florida National Guard survey who had probable deployment 
related TBI (N = 146). A fourth sample used for cross-validation included 206 veterans 
presenting to military TBI clinics for neuropsychological evaluation. All participants in 
this latter sample completed the Personality Assessment Inventory (PAI) and were 
classified as valid (n = 161) or invalid responders (n = 45) based on the cut score of 75 or 
higher on the PAI Negative Impression Management (PAI NIM) scale. Of the three 
developed NSI subscales, Validity-10 best classified participants overall, with moderately 
high sensitivity of .61 and high specificity of .85 at a cut score of greater than 22. 
Lange et al. (2015) performed a head-to-head comparison of Validity-10 and the 
mBIAS in a prospective study of 63 combat veterans diagnosed with mTBI. Participants 
were placed in criterion groups of SVT-pass (n = 39) and SVT-fail (n = 24) based on 8 of 
the 10 validity scales of the Minnesota Multiphasic Personality Inventory – Restructured 
Form (MMPI-2-RF).  Participants were excluded based on high Cannot Say scores and 
VRIN-r/TRIN-r scores. The mBIAS produced an optimal cut score of ≥ 8 and showed 
poor sensitivity of .17 and excellent specificity of 1.0. Validity-10 produced an optimal 
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cut score of ≥ 13, which showed moderately high sensitivity of .63 and excellent 
specificity of .97. The group (which had developed the mBIAS) rejected the mBIAS in 
favor of Validity-10. Lange et al. (2016) replicated the cross-validation study of 
Vanderploeg et al. (2014) in a sample of 272 U.S. military veterans with mild, moderate, 
or severe TBI. Using the cut score of PAI NIM ≥ 75 to create criterion groups, the study 
found Validity-10 to best classify participants at a cut score of ≥ 19, having moderately 
high sensitivity of .59 and very high specificity at .89. 
The present study would seek to replicate and extend the validity information 
obtained by prior studies by employing NSI data obtained directly from the VHA CTE 
process, multiple measures of symptom and performance validity, and a direct analysis of 
the extent to which PTSD symptoms may affect the test operating characteristics of 
Validity-10. 
Aim & Objectives 
The aim of this study is to examine the test validity of the Validity-10 subscale 
(Vanderploeg, 2014) of the Neurobehavioral Symptom Inventory (NSI; Cicerone & 
Kalmar, 1995) for detecting invalid responses during evaluation of veterans for mild 
traumatic brain injury (mTBI). The objectives of the study are: 
(1) to estimate the sensitivity and specificity of Validity-10 at the recommended
cut scores for identifying questionably valid test profiles as determined by tests of 
cognitive symptom validity and performance validity; 
(2) to estimate the sensitivity and specificity of Validity-10 at the recommended
cut scores for identifying questionably valid test profiles as determined by tests of 
psychiatric symptom validity; 
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(3) to estimate the sensitivity and specificity of Validity-10 at the recommended
cut score for identifying questionably valid test profiles determined by failure of 
SVTs or PVTs, regardless of cognitive or psychiatric domain; 
(4) to characterize the clinical utility of Validity-10 by calculating its test
operating characteristics in a representative sample at several realistic benchmark 
base rates of invalid responding; and 
(5) to determine the extent to which the presence of PTSD symptoms affects the
test operating characteristics of Validity-10. 
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Table 2.1: WHO Classification of Traumatic Brain Injury Severity 
Severity Duration of LOC GCS Score Duration of PTA 
Mild < 30 m 13-15 < 24 h 
Moderate 30 m - 24 h 9-12 1-7 d
Severe > 24 h 3-8 > 7 d
Note. GCS score is the lowest score obtained 30 minutes or longer after injury. LOC = 
loss of consciousness; GCS = Glasgow Coma Scale; PTA = post-traumatic amnesia; d = 
days; h = hours; m = minutes. 
20 
Chapter 3—Methods 
Parent Study  
Data for the proposed study were obtained as part of a multi-site VA study 
(“Evaluation of VA’s TBI Clinical Reminder and Comprehensive TBI Evaluation”; 
Babcock-Parziale, Pape, High, Smith, Evans, and McKnight, 2010). The objectives of the 
parent study were (1) to develop an Experts’ Diagnostic Assessment Battery, including a 
neuropsychological battery and clinical diagnostic criteria, for combat mTBI and PTSD; 
(2) to evaluate test operating characteristics of the VA TBI Clinical Reminder (TCR)
screening tool and the physician-administered Comprehensive TBI Evaluation (CTE) 
with respect to the EDAB; (3) to examine the concordance of the neuropsychological 
battery (measuring objective cognitive symptoms) with the NSI and the validity of both 
the neuropsychological battery and the NSI for predicting outcome on the CTE; (4) to 
examine the relation between CTE results and functional outcomes as measure by self-
report inventories of sleep, general health, disability, and community participation; (5) 
examine the concurrent validity of EDAB classification with respect to functional 
impairment measures; and (6) to determine the one-week test-retest reliability of the TCR 
and CTE. In pursuit of those aims, the research team collected from a sizable sample of 
recent veterans a wealth of objective and self-report data pertinent to risk factors, 
diagnosis, and cognitive, affective, somatic, and other functional outcomes of combat 
PTSD and mTBI. This section will describe the participants, procedures, and measures 
included in the parent study, with particular attention to those most pertinent to the 
proposed project. 
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Parent study participants. Veterans of OEF/OIF were recruited by letter or 
clinical contact from three VA Polytrauma Network Sites (Southern Arizona VA Health 
Care System in Tucson, AZ, Hines VAMC in Chicago, IL, and Lexington VAMC in 
Lexington, KY). Following receipt of a HIPAA waiver, OEF/OIF program managers 
were contacted for a list of OEF/OIF veterans in each of the three catchment areas. 
Investigators were also notified of new enrollments in VA Polytrauma services at each 
site. The research team sent a letter to each veteran to allow the individual to opt out of a 
follow-up recruitment telephone call. Those for whom an opt-out response was not 
received within three weeks were contacted by study staff to complete a telephone 
screening. Study recruitment brochures were also distributed to community-based 
outpatient clinics affiliated with each site to invite potential participants to contact study 
staff. Potential recruits were excluded from participation who (1) were enrolled in 
another research study, the principal investigator of which would not approve concurrent 
this concurrent enrollment; (2) had been treated for concussion within the last 30 days; 
(3) had been diagnosed with moderate or severe TBI; or (4) were unable to read and
respond in English, the only language for which all study instruments were validated. 
Participants demonstrated understanding that the study was to evaluate the VAs 
assessments for mTBI; that participants must be OEF/OIF veterans; that this was not a 
treatment study; that the study would require the participant to visit a VA site for 8 hours 
of assessments (including breaks), that the participant would be asked about deployment 
experiences, health, and wellbeing; and the participant would receive up to $160 for 
participation in the study. These details were reiterated during further informed consent 
procedures on the day of testing. 
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Procedures. The initial selection of measures and diagnostic criteria for inclusion 
in the Expert Diagnostic Assessment Battery (EDAB) was a result of an expert panel 
under the online Delphi paradigm. Two panels of eight VA and non-VA clinicians 
treating mTBI patients were assembled based on peer-reviewed publications and 
experience diagnosing and treating persons with mTBI. The first panel included 
physiatrists, behavioral neurologists, clinical neuropsychologists, neuropsychiatrists, 
nurse practitioners, and speech pathologists and was responsible for selecting clinical 
diagnostic criteria for mTBI. The second panel included only clinical neuropsychologists 
and was responsible for selecting a battery of neuropsychological tests with utility for 
evaluation of mTBI. Research team members assembled an updated review of the 
research on mTBI diagnosis, which was provided to the expert panel members for 
briefing (Pape et al., 2013). Under the Delphi paradigm, panel members were 
independently asked for ratings of the utility of different questions and instruments for 
diagnosing mTBI. Ratings were compiled and iteratively distributed to panel members 
for consideration and follow-up rating until consensus was reached. The result was the 
EDAB, a battery of neuropsychological tests and clinical criteria selected by expert 
consensus to serve as a proxy “gold standard” for diagnosis of mTBI in the absence of a 
generally accepted “gold standard.” 
To briefly review VA policy: all returning OIF/OEF veterans complete the TBI 
Clinical Reminder screening questionnaire upon contact with the VA health system. 
Those who screen negative for combat TBI continue with VA care as usual. Those who 
screen positive undergo a CTE administered by a VA Polytrauma physician. Results of 
the TBI Clinical Reminder and the physician-administered CTE are recorded in the VA 
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electronic medical record. The NSI is administered during the CTE. Participants in the 
parent study who received a positive TBI Clinical Reminder screening result completed 
the study measures within 30 days of completing the CTE. To ensure that all study 
participants completed the same measures, participants who received a negative TBI 
Clinical Reminder screening result underwent a CTE with a physician on the research 
team on the day of research testing. On the day of research testing, all participants 
completed the EDAB, which included neuropsychological testing, standalone 
performance validity testing (Letter Memory Test), embedded symptom validity testing 
(MMPI-2-RF validity scales), and a structured interview for TBI diagnosis; the Clinician 
Administered PTSD Scale, which is a structured interview for PTSD diagnosis; and a set 
of self-report questionnaires to collect demographic, mood, and functional outcome data.  
Measures Relevant to Present Study 
TBI Clinical Reminder. The TBI Clinical Reminder is a set of four self-report 
questions administered by oral interview of veterans by VHA healthcare professionals 
(Belanger, Uomoto, and Vanderploeg, 2009). It serves as a screening measure to rule out 
a history of traumatic brain injury. Respondents with a positive answer on all four of the 
items are referred to a TBI physician for more thorough evaluation in the Comprehensive 
TBI Examination. The four questions are as follows: (1) Did you have any injury(ies) 
during your deployment from any of the following? (check all that apply: fragment, 
bullet, explosion, etc), (2) Did any injury you received while deployed result in any of the 
following? (check all that apply: head injury, feeling dazed, not remembering the injury, 
etc.), (3) Did any of these begin or get worse afterward? (check all that apply: problems 
with balance, memory, sleep, etc.), and (4) In the past week, have you had any of the 
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above symptoms? (check all that apply: problems with dizziness, memory, etc.). Belanger 
et al. (2012) examined the evidence for utility of the TBI Clinical Reminder using results 
of the secondary TBI evaluation as a criterion measure. Sensitivity (SN = 0.87 - 0.90) and 
negative predictive value at an estimated base rate of 15% (NPV = 0.89) were very good. 
Specificity (SP =  0.13 – 0.18) and positive predictive value (PPV = 0.16) were extremely 
poor, limiting acceptable use of the TBI Clinical Reminder to screening situations alone. 
Neurobehavioral Symptom Inventory. The Neurobehavioral Symptom 
Inventory (NSI; Cicerone and Kalmar, 1995) is a self-report questionnaire that assesses 
the presence and severity of 22 nonspecific sequelae of TBI. The test taker rates on a 
five-point scale how much each symptom has disturbed him or her in the past month. 
Domains assessed include cognitive, affective, physical, and pain symptoms. The NSI is 
administered as part of the VHA Comprehensive TBI Examination, so the data are 
available for veterans who screen positive on the TBI Clinical Reminder before the 
physician determines the need for a referral to more intensive “secondary TBI 
evaluation” by a multidisciplinary team including a clinical neuropsychologist. Meterko 
et al. (2012) conducted a confirmatory factor analysis of NSI responses in a large sample 
of VHA patients and found support for a four-factor model (“Somatosensory,” 
“Cognitive,” “Affective,” and “Vestibular”). Vanderploeg et al. (2015) confirmed this 
four-factor model in two large VHA and DOD samples of veterans. The same group 
presented normative data for NSI in this population (Soble et al., 2014). Psychometric 
studies of the Validity-10 subscale of the NSI were detailed above, in the “Current 
Practice and Research” section of the literature review. The Validity-10 includes 10 items 
relating to hearing problems, noise sensitivity, change in taste or smell, difficulty making 
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decisions, slowed thinking, dizziness, balance problems, coordination difficulties, nausea, 
and vision problems. 
Letter Memory Test. The Letter Memory Test (LMT; Inman et al., 1998) is a 
stand-alone, forced-choice performance validity test designed to be insensitive to 
neurological compromise while retaining face validity as a test of memory. In reality, 
success on the task relies upon recognition memory, which is relatively preserved in most 
neurological disorders. Test duration is about 15-20 minutes. The test taker is presented 
with a string of letters, then a 5-second delay, and then a set of options from which to 
select the presented string. Over the course of the test, the number of multiple-choice 
options increases from two, to three, and finally to four, and the string length increases 
from three letters, to four, to five, giving the impression of increasing difficulty. The 
recommended cut score for detecting invalid responding is a total percentage correct 
below 93%. Under both simulation and known-groups designs, the LMT has consistently 
demonstrated excellent specificity and moderate to high sensitivity to feigned sequelae of 
TBI (Inman et al., 1998; Greub and Suhr 2006; Vagnini et al., 2006, Schipper, Berry, 
Coen, and Clark, 2008; Sollman and Berry, 2011). 
California Verbal Learning Test—Second Edition. The California Verbal 
Learning Test—Second Edition (CVLT-II; Delis, Kramer, Kaplan, and Ober, 2000) 
consists of a five-trial verbal list-learning task, followed by immediate and delayed recall 
trials, a recognition task of target words among distraction items, and a forced choice 
recall trial included as a performance validity index. The parent study did not include the 
forced choice recall trial, which would have been ideal for inclusion as an embedded 
performance validity index; however, the Total from the learning trials (Trials 1-5) and 
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Recognition Discriminability (d′) scores from the recognition trial have performed well 
as embedded validity measure in the prior edition of the test (Millis, Putnam, Adams, and 
Ricker, 1995; Sweet et al., 2000; Demakis, 2004), and the d′ score from the current 
revision has been included as a useful index in logistic regression-based formulas for 
detecting invalid performance (Wolfe et al., 2010). The present study will employ cut 
scores of CVLT-II Total ≤ 34 and CVLT-II d′ ≤ 0.81 as indices of questionable 
performance validity. These are empirically derived cut scores on the original CVLT 
(Millis, Putnam, Adams, and Ricker, 1995) and may be applied to the CVLT-II because 
the two tasks have nearly identical demands. The d′ score is essentially a proportion of 
errors a (sum of misses and false positives divided by total items); it is by definition 
scaled to the total number of task items, so interpretation of the score should be nearly 
identical under either task.  
Minnesota Multiphasic Personality Inventory—2—Restructured Form. The 
Minnesota Multiphasic Personality Inventory—2—Restructured Form (MMPI-2-RF; 
Tellegen and Ben-Porath, 2008; Ben-Porath, 2012) is a 338-item, true-or-false, self-report 
questionnaire designed to assess personality and psychopathology symptoms. Test 
duration is about 30-45 minutes. Test items were extracted from the MMPI-2 based on a 
factor analysis and used to construct ten factor-specific clinical scales and three higher-
order clinical scales. The test includes several embedded validity scales designed to 
detect content-nonresponsive feigning (VRIN-r, TRIN-r) and both faking bad (F-r, Fp-r, 
Fs, FBS-r) and faking good (L-r and K-r) response styles. The faking bad scales in 
particular have demonstrated large effect sizes for identifying overreporting in civil 
forensic settings (Wygant et al., 2011). Because there is no well-validated alternative cut 
27 
score for overreported TBI the present study will use the recommended cut scores of F-r 
≥ 120, Fp-r ≥ 100, Fs ≥ 100, and FBS-r ≥ 100 from the test manual to determine 
questionable validity according to the MMPI-2-RF. Specifically, Fp-r and Fs will be used 
as indicators of psychiatric symptom validity, whereas F-r and FBS-r will be used as 
indicators of cognitive symptom validity, in accordance with prior research (Gervais, 
Wygant, Sellbom, and Ben-Porath, 2011; Rogers, Gillard, Berry, and Granacher, 2011).  
Miller Forensic Assessment of Symptoms Test. The Miller Forensic 
Assessment of Symptoms Test (M-FAST; Miller, 2001) is a structured interview 
designed to detect malingered psychiatric presentations. The 25 items were selected to 
represent the various approaches to psychiatric malingering described by Rogers (1997). 
The M-FAST has been validated extensively for use in legal contexts. The cutoff score 
recommended in the manual demonstrated good specificity (greater than 0.80) and 
excellent sensitivity (greater than 0.90) in initial validation studies (Miller, 2001). The 
present study will employ the cutoff score of Total ≥ 6 recommended in the test manual 
as an indicator of questionable psychiatric symptom validity.  
Clinician-Administered PTSD Schedule. The Clinician-Administered PTSD 
Schedule (CAPS; Blake et al., 1995) is a structured interview for posttraumatic stress 
disorder, widely considered to be the “gold standard” for PTSD diagnosis. The CAPS 
first uses a questionnaire to screen for whether the test taker meets Criterion A of the 
DSM-IV PTSD diagnostic criteria. Test takers who meet Criterion A are interviewed 
regarding the frequency, intensity, and event-relatedness of symptoms relevant to Criteria 
B, C, and D of the diagnosis. Final interview questions assess Criterion E (duration of 
symptoms), Criterion F (functional impairment due to symptoms), and Specifiers 
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(delayed-onset, chronic, acute) for the diagnosis. Weathers, Ruscio, and Keane (1999) 
evaluated nine different scoring rules for the CAPS and found all nine rules to 
demonstrate very good to excellent reliability in two independent administrations. The 
researchers recommended that the scoring rules, which varied by leniency, be selected 
and defended according to the clinical or research task at hand. To err on the side of 
inclusivity because of the possible presence of disruptive, subclinical posttraumatic stress 
symptoms in the population, the present study will employ the “lenient scoring rule” 
(frequency ≥ 1 and intensity ≥ 2) to determine the presence of self-reported PTSD 
symptoms sufficient for a diagnosis.  
Analytic Procedure 
Pape et al. (2016) reported on the utility of a diagnostic algorithm generated as a 
part of the parent study. The report did include a brief comparison of two cut scores of 
the NSI Validity-10 and their effects on performance of the algorithm. The report did not, 
though, examine the test operating characteristics of the NSI Validity-10 in sufficient 
detail to cross-validate its use among veterans who screened positive in the TBI clinical 
reminder. The sample for the present study includes only participants who screened 
positive for TBI follow-up using the TBI Clinical Reminder. Participants with invalid 
MMPI-2-RF profiles due to content nonresponsive feigning (VRIN-r ≥ 80 or TRIN -r ≥ 
80) were excluded from analyses. For each participant, a Validity-10 score was computed
based on NSI data. Test signs on SVTs and PVTs were tallied using the cut scores noted 
above. For each participant, the number of positive SVT/PVT signs was then totaled 
within the cognitive symptom/performance domain and within the psychiatric symptom 
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domain. The number of positive SVT/PVT test signs overall, regardless of domain, was 
also totaled. 
For the first three study objectives, sensitivity and specificity of Validity-10 was 
computed for the previously studied cut scores of ≥13, ≥19, and >22. These analyses 
were performed using six different criterion rules to determine questionable validity 
(QV): production of “one or more” positive test signs in the cognitive domain only, in the 
psychiatric domain only, or irrespective of domain, and production of “two or more” 
positive test signs in the cognitive domain only, in the psychiatric domain only, or 
irrespective of domain. Results were used to select an “optimal” Validity-10 cut score for 
further analyses. For the fourth study objective, positive and negative predictive values of 
the optimal Validity-10 cut score were computed under each criterion rule at three 
realistic benchmark base rates of invalid responding in the population. For the fifth and 
final study objective, participants were classified by PTSD diagnosis based on self-
reported symptoms per the Clinician Administered PTSD Scale (CAPS). Overall 
accuracy, false positive rate, and false negative rate of the Validity-10 optimal cut score 
were calculated within PTSD status group under both the “any one” or “any two” rule for 
QV. To test the statistical significance of differences between these rates across PTSD 
status, participants were cross-tabulated according to PTSD diagnosis and accurate or 
inaccurate classification by the optimal Validity-10 cut score under both the “any one” or 
“any two” positive test sign criterion rules. For each cross-tabulation, a chi-square test 
was performed to examine the association between reported PTSD symptoms and 
classification accuracy of Validity-10.  
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Chapter 4—Results 
From the parent study sample of 438 participants, 22 were excluded for content 
non-responsive feigning indicated by elevation of the VRIN-r or TRIN-r scale of the 
MMPI-2-RF. One additional participant was excluded for having incomplete 
neuropsychological data, and a further two participants were excluded for having NSI 
data entirely missing. Nine participants had missing data for no more than 1 of the 22 
NSI items, and those data points were converted to zero to retain the bulk of the data for 
those individuals while reflecting the lack of endorsement of symptoms for which data 
were missing. Of the remaining 413 participants, only the 177 who screened positive for 
TBI using the TBI Clinical Reminder were included in the present analyses, unless 
otherwise indicated. 
The sample (N = 177) was predominantly male (93.8%), with a median age of 
27.0 years (M = 30.0; SD = 8.03) and a bimodal distribution of education level, with 
peaks at 12 years and 14 years (M = 13.5; SD = 1.54). The reported racial/ethnic makeup 
of the sample was 72.3% white (not Hispanic or Latino), 20.9% Hispanic or Latino, 8.5% 
Black or African American, 10.2% more than one race/ethnicity, and 9.1% other or 
unspecified. The mean estimated WAIS-III Full Scale IQ, based on the WTAR, was 
102.6 (SD = 8.30).  
Table 4.1 shows the computed base rates of questionable validity in the sample as 
measured by production of either one or two positive test signs on indicators in the 
cognitive domain, the psychiatric domain, or either/both domains. Across domains, the 
measured base rate was higher using the laxer criterion of “one or more positive test 
sign” rather than the more stringent criterion of “two or more positive test signs.” 
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Conversely, regardless of the number of positive test signs chosen, the measured base 
rate was higher when considering both the cognitive and psychiatric domains together 
rather than separately. These trends are in line with expectations given the relative 
stringencies of the criteria employed. For the interested reader, cross-tabulations of single 
SVT/PVT test signs are provided in Appendix 1. 
Table 4.2 displays the computed sensitivity and specificity of each of three 
proposed Validity-10 cut scores for detecting questionable validity as measured by the 
various criteria presented above. As expected, a lower cut score generally exhibited 
higher sensitivity and lower specificity, whereas the reverse was true of a higher cut 
score. Also as expected, regardless of the cut score, Validity-10 was more sensitive to 
questionable validity as measured by more stringent criteria. Specificity did not appear to 
be affected notably by stringency of the criteria for questionably validity. Using the 
criterion of one or more positive test sign, a cut score of Validity-10 > 22 resulted in 
excellent specificity and poor sensitivity across domains. A cut-score of Validity-10 ≥ 19 
demonstrated high specificity and moderate sensitivity across domains, with sensitivity 
notably higher for questionable validity in the cognitive domain. A cut-score of Validity-
10 ≥ 13 resulted in quite high sensitivity but unacceptably low specificity. Using the 
more stringent criterion of two or more positive test signs, specificity followed a similar 
pattern across domains, but sensitivity was higher overall. Sensitivity at a high level of 
specificity was optimal for a cut score of Validity-10 ≥ 19 overall, reaching a moderately 
high range of about .55-.60 in the psychiatric and combined domains and nearly perfect 
range in the cognitive domain. 
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As explained in the Methods section above, predictive values answer the clinical 
question of how likely the test result is to give a correct classification. Unlike sensitivity 
and specificity, predictive values vary along with the base rate. Table 4.3 displays the 
positive and negative predictive values (PPV and NPV) of the optimal cut score 
(Validity-10 ≥ 19) at several benchmark base rates of the various criteria for questionable 
validity. The salient trend is that under all criteria of questionable validity, PPV improved 
from moderate to moderately high as the benchmark base rates increased toward 50%. 
NPV diminished slightly from very high to moderately high as base rate increased. The 
one exception is that NPV for QV defined as two or more positive test signs in the 
cognitive domain remained excellent across base rates. Predictive values were similar 
across number of positive test signs required for questionable validity. Predictive values 
were slightly better for QV in the cognitive domain than those for QV in the combined 
domains, which in turn were slightly better than those for QV in the psychiatric domain. 
For the interested reader, cross-tabulations of single SVT/PVT results by Validity-10 test 
sign (using the cut score Validity-10 ≥ 19) are provided in Appendix 2. 
In order to determine whether reported presence of PTSD symptoms influences 
the test operating characteristics of Validity-10, several accuracy indices were computed 
separately for those participants who met the lenient CAPS criterion for PTSD and for 
those who did not. These accuracy indices, presented in Table 4.4, were computed for the 
optimal Validity-10 cut score (Validity-10 ≥ 19) under both the “Any 1” and “Any 2” 
criterion rules for QV. Visual examination of these values suggests that the Validity-10 
may be more accurate overall and have a lower false positive rate among those without 
significant reported PTSD symptoms than among those who do report a significant level 
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of PTSD symptoms. The reverse appears to be true, however, regarding false negative 
rate. The effects appeared to stand whether using failure of “one or more positive 
SVT/PVT test sign” or “two or more positive SVT/PVT test signs” as criteria for 
questionable validity. Overall accuracy and false negative rate did appear to improve 
somewhat under the more stringent “two or more” criterion. 
To test the statistical significance of these between-groups differences follow-up 
cross-tabulations and Bonferroni-corrected Pearson chi-square tests were performed, 
treating overall classification errors, false positives, and false negatives separately.   
Examination of these results in Table 4.5 further clarifies the effects. The differences 
across PTSD group in total classification accuracy and false positive rate were found to 
be significant at the p < .05 level, even after adjusting for multiple tests. The difference in 
false negative rate across PTSD groups was not found to be significant at the p < .05 
level. These results suggest that Validity-10 does perform more poorly among those who 
report more significant PTSD symptoms, particularly because more false positives for 
QV are generated in that population. On the other hand, PTSD diagnosed by structured 
interview did not significantly increase the risk of false negative Validity-10 results, at 
least among this sample of veterans referred due to a positive TBI screen. The same 
pattern of effects appeared regardless of whether the “one or more” or “two or more” 
PVT/SVT failure rule was used to determine QV. 
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Table 4.1: Base rates of questionable validity by domain and number of positive test 
signs 
Criterion Base Rate (%) 
At least 1 positive: 
   Cognitive PVT/SVT 24.3 
   Psychiatric SVT 24.3 
   Cognitive or Psychiatric PVT/SVT 34.5 
At least 2 positive: 
   Cognitive PVTs/SVTs 7.34 
   Psychiatric SVTs 6.78 
   Cognitive or Psychiatric PVT/SVT 18.6 
Note. The table displays the base rates of questionable response validity found in the 
study sample using several different criteria for questionable response validity. PVT = 
performance validity test; SVT = symptom validity test. 
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Table 4.2: Sensitivity and specificity of Validity-10 by cut score and criterion 
Validity-10 ≥ 13 Validity-10 ≥ 19 Validity-10 > 22 
SENS SPEC SENS SPEC SENS SPEC 
At least 1 positive: 
    Cognitive PVT/SVT 76.7 63.4 55.8 86.6 23.3 94.8 
    Psychiatric SVT 65.1 59.7 41.9 82.1 20.9 94.0 
    Cognitive or Psychiatric PVT/SVT 70.5 66.4 44.3 87.1 19.7 95.7 
At least 2 positive: 
    Cognitive PVT/SVT 100 57.9 92.3 81.7 46.2 93.3 
    Psychiatric SVT 91.7 57.0 58.3 78.8 33.3 92.1 
    Cognitive or Psychiatric PVT/SVT 78.8 61.1 57.6 84.0 30.3 95.1 
Note. Sensitivity and specificity are reported as percentages. SENS = sensitivity; SPEC = specificity. PVT = performance validity test; 
SVT = symptom validity test. 
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Table 4.3: Predictive values of Validity-10 (≥ 19) at varying base rates 
Base Rate = .20 Base Rate = .30 Base Rate = .40 
PPV NPV PPV NPV PPV NPV 
At least 1 positive: 
    Cognitive PVT/SVT 51.0 88.7 64.0 82.1 73.5 74.6 
    Psychiatric SVT 36.9 86.0 50.0 76.7 60.9 67.9 
    Cognitive or Psychiatric PVT/SVT 46.1 86.2 59.5 78.5 69.5 70.1 
At least 2 positive: 
    Cognitive PVT/SVT 55.8 97.7 68.4 96.1 77.1 94.1 
    Psychiatric SVT 40.7 88.3 54.1 81.5 64.7 73.9 
    Cognitive or Psychiatric PVT/SVT 47.4 88.8 60.7 82.2 70.6 74.8 
Note. Predictive values are reported as percentages. PPV = positive predictive value; NPV = negative predictive value; PVT = 
performance validity test; SVT = symptom validity test. 
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Table 4.4, Panels a-b: Validity-10 accuracy rates by PTSD status 
(a) Validity-10 accuracy rates by PTSD status using “Any 1” QV criterion
Overall Accuracy False Positive Rate False Negative Rate 
No PTSD 84.62 3.64 80.00 
PTSD 65.17 21.31 50.98 
    Total 72.31 12.93 55.74 
(b) Validity-10 accuracy rates by PTSD status using “Any 2” QV criterion
Overall Accuracy False Positive Rate False Negative Rate 
No PTSD 93.85 3.28 50.00 
PTSD 70.54 25.30 41.38 
    Total 79.10 15.97 42.42 
Note. ‘“Any 1” rule’ denotes use of one or more positive test sign on symptom validity 
and performance validity tests as the criterion for questionable response validity. ‘“Any 
2” rule’ denotes use of two or more positive test signs on symptom validity and 
performance validity tests as the criterion for questionable response validity. PTSD = 
post-traumatic stress disorder criteria met per CAPS lenient criterion. 
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Table 4.5, Panels a-f: Cross-tabulations and tests of Validity-10 accuracy by PTSD status 
(a) Validity-10 overall accuracy (“Any 1” rule) by PTSD status
Validity-10 
and 
Criterion 
Concordant 
Validity-10 
and 
Criterion 
Discrepant Totals χ2 p value 
No PTSD 55 10 65 
PTSD 73 39 112 
    Totals 128 49 177 
7.76 .005* 
(b) Validity-10 overall accuracy (“Any 2” rule) by PTSD status
Validity-10 
and 
Criterion 
Concordant 
Validity-10 
and 
Criterion 
Discrepant Totals χ2 p value 
No PTSD 61 4 65 
PTSD 79 33 112 
    Totals 140 37 177 
13.52 < .001* 
(c) Validity-10 false positives by PTSD status among non-QV participants (“Any 1”
rule)
Validity-10 
True 
Negative 
Validity-10 
False 
Positive Totals χ2 p value 
No PTSD 53 2 55 
PTSD 48 13 61 
    Totals 101 15 116 
8.03 .005 * 
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Table 4.5, Panels a-f (Continued) 
(d) Validity-10 false positives by PTSD status among non-QV participants (“Any 2”
rule)
Validity-10 
True 
Negative 
Validity-10 
False 
Positive 
Totals 
χ2 p value 
No PTSD 59 2 61 
PTSD 62 21 83 
    Totals 121 23 144 
12.71 < .001 * 
(e) Validity-10 false negatives by PTSD status among QV participants (“Any 1” rule)
Validity-10 
True 
Positive 
Validity-10 
False 
Negative Totals χ2 p value 
No PTSD 2 8 10 
PTSD 25 26 51 
    Totals 27 34 61 
2.85 .091 
(f) Validity-10 false negatives by PTSD status among QV participants (“Any 2” rule)
Validity-10 
True  
Positive 
Validity-10 
False 
Negative Totals χ2 p value 
No PTSD 2 2 4 
PTSD 17 12 29 
    Totals 19 14 33 
.017 .744 
Note. ‘“Any 1” rule’ denotes use of one or more positive test sign on symptom validity 
and performance validity tests as the criterion for questionable response validity. ‘“Any 
2” rule’ denotes use of two or more positive test signs on symptom validity and 
performance validity tests as the criterion for questionable response validity. PTSD = 
post-traumatic stress disorder criteria met per CAPS lenient criterion. *significant at p < 
.05, one-tailed, Bonferroni-corrected for familywise error across six tests. 
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Chapter 5—Discussion 
Primary Findings 
The present study employed a modified known-groups design and a clinically 
relevant sample of veterans in the VHA system to cross-validate the Validity-10 for 
detecting questionable response validity (QV) among veterans being evaluated for mild 
TBI. Primarily, the study sought to estimate the sensitivity and specificity of Validity-10 
to QV at several suggested cut scores and, in turn, to estimate the positive and negative 
predictive values of the best performing cut score under several realistic benchmark base 
rates. Results suggested that under more stringent criteria for questionable validity, a cut 
score of Validity-10 ≥ 19 exhibited good specificity and moderate to moderately high 
sensitivity for QV regardless of whether psychiatric or cognitive symptom report or 
performance were invalid. Predictive values demonstrated that use of the Validity-10 ≥ 
19 cut score at several realistic benchmark base rates presented a modest improvement in 
negative predictive value and a substantial improvement in positive predictive value, 
versus simply assuming valid performance and symptom report (i.e., “going with the base 
rate”). 
Broadly speaking, these findings are in line with the growing consensus that 
Validity-10 performs well as an SVT (Vanderploeg et al., 2014; Lange et al., 2015; 
Lange et al., 2016). At a finer level of detail, the present findings differ from prior 
research in notable ways. First, Vanderploeg et al. (2014) recommended a cut score of 
Validity-10 > 22, which in that study exhibited moderately high sensitivity and high 
specificity. That cut score indeed showed excellent specificity in the present study, but 
sensitivity was unacceptably low (.20 - .30) in most domains. Vanderploeg et al. (2014) 
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employed only one criterion measure (Personality Assessment Inventory – Negative 
Impression Management; PAI-NIM), which was primarily a psychiatric SVT. Lange et 
al. (2015) reported moderately high sensitivity and excellent specificity, albeit for a cut 
score of Validity-10 ≥ 13, using 8 of the 10 MMPI-2-RF validity scales as criterion 
measures. That cut score exhibited quite high sensitivity in the present study (> .65), but 
specificity was unacceptably low (.55 - .70). The criterion measures employed in that 
study were representative of both the psychiatric and cognitive symptom domains but 
were limited to the MMPI-2-RF and included no stand-alone SVT-PVTs. Finally, Lange 
et al. (2016) replicated the Vanderploeg et al. (2014) study in a sample of veterans, using 
the PAI-NIM as the sole criterion measure and recommended a cut score of Validity-10 ≥ 
19, which displayed moderately high sensitivity and very high specificity. The present 
findings nearly exactly replicate that recommended cut score and its operating 
characteristics, with the added benefit of multiple SVT/PVT modalities in both the 
cognitive and psychiatric domains. 
Moreover, the present study found that utility of the Validity-10 was highest 
(sensitivity nearly perfect) for QV cognitive symptoms and performance, whereas 
sensitivity to QV psychiatric symptoms was more moderate. This disparity does not 
appear to have been identified or studied before the present study. Although one study 
(Lange et al., 2015) did include criterion measures of both psychiatric and cognitive 
symptom validity, the analyses did not distinguish between psychiatric and cognitive QV. 
The other two studies (Vanderploeg et al., 2014; Lange et al., 2016) relied only upon a 
measure of psychiatric symptom validity as a criterion measure. Unfortunately, there are 
no prior results with which to compare the present finding of surprisingly good 
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performance of Validity-10 for detecting strictly cognitive QV. If that effect is non-
spurious, future validation studies will only be able to replicate it if care is taken to 
distinguish between cognitive and psychiatric QV. Be that as it may, even the relatively 
weaker predictive values for QV psychiatric symptoms in the present findings did 
indicate a modest improvement over assuming valid psychiatric symptom report, 
suggesting that use of Validity-10 where only the authenticity of psychiatric symptoms is 
in question would be preferable to—and would at least cause no more harm than—“going 
with the base rate.” Indeed, perhaps unintentionally, detection of psychiatric QV has the 
strongest research support in the current Validity-10 literature. 
Given that within the VHA system there is often a question of comorbid PTSD 
symptomatology during evaluations for mild TBI, the present study sought to determine 
whether such symptoms might affect the utility of Validity-10 in those evaluations. The 
findings suggest that regardless of the stringency of criteria for QV, the presence of 
PTSD symptoms was associated with an increase in false positive identification by 
Validity-10. These findings suggest that individuals who report significant traumatic 
stress symptoms are more likely to produce a positive SVT/PVT sign. There exists the 
possibility that production of positive test signs represents “false positive” activity in 
which SVT/PVTs are unduly sensitive to genuine symptoms. Conversely, there exists the 
alternative possibility that those who report PTSD symptoms do fake bad, and do so in 
such a manner that they are more difficult to detect with SVT/PVTs. The present study 
does not allow for conclusion in one direction more than the other. Perhaps both 
phenomena are at work. Nonetheless, the present findings suggest that the presence of 
reported PTSD symptoms can affect the test operating characteristics of Validity-10, and 
43 
further studies would be required to better characterize the effect. If the latter case is 
true—that individuals reporting more PTSD symptoms are more likely faking bad—then 
future studies should explore using more sensitive SVT/PVTs (or more sensitive cut 
scores) as criterion indicators for QV. To date, no validation study of Validity-10 has 
attempted to measure the effect of PTSD symptoms on test operating characteristics. 
Limitations 
Use of a known groups design in this study raises concerns about internal validity. 
There was no experimental manipulation of participants’ response styles, thus there can 
be no comparison of performance before and after a manipulation, nor across groups who 
performed under only one experimental condition. The observational nature instead limits 
us to an approximation of response style as a quasi-experimental “condition” identified 
using post-hoc criteria. The trade-off in using a known groups design is the gain in 
external validity. The participants are part of the real-world population under study. They 
do not simulate response styles; they merely have them. Where the simulation design 
introduces an additional assumption in asking participants to take on a response style to 
better control the experimental condition, the known groups design elects to take 
advantage of real-world expression of response styles, introducing the assumption of 
accurate identification of those response styles down the line. Still, the criticism carries 
weight. Thus, best practice for validation of SVT/PVTs is to perform both types of study 
and to critically evaluate the results at a meta-analytic level. Validation of the NSI 
Validity-10 would benefit from further studies following a clinically enhanced simulation 
design, in which the performance of honest performers with mild TBI diagnoses is 
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compared with the performance of participants without mild TBI instructed to simulate 
mild TBI symptoms.  
The present study was an attempt to improve on past studies by including as 
criterion measures several SVT/PVTs in both the cognitive and psychiatric domains. On 
this front, though, the study would have been improved had the criterion SVT/PVTs been 
more standard and better validated. Because the data for the study were drawn from a 
pre-existing clinical research study, the choice of criterion measures was limited to 
instruments administered in the parent study. Moreover, the present study fell prey to a 
practical problem often found in secondary data analysis—that despite more ideal 
measures having been administered (e.g. CVLT-II Forced Choice), the data from those 
measures were not available in the database simply because they were not of primary 
interest in the parent study. Original records were inaccessible due to variable 
information security practices across the multiple VA sites, and so substitute measures 
were identified. On one hand, it is true that a prospective study designed from scratch to 
answer the research questions would have been ideal; on the other hand, accepting some 
trade-offs allowed examination of test operating characteristics in a highly relevant 
clinical sample. To abandon the analysis because of an unwillingness to adapt would 
have been an opportunity lost. Such is the reality of secondary data analysis in clinical 
research. 
Another limitation of the present study is that the choice of the “lenient” criteria 
for PTSD diagnosis on the CAPS was somewhat arbitrary. This is both true and 
unavoidable. A trivial point is that neither the “moderate” nor the “strict” criteria would 
have been less arbitrary. The rationale behind employing the lenient criteria was that the 
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presence of considerable traumatic stress symptoms, even if PTSD criteria were not fully 
met, may affect the results on tests sensitive to mild TBI symptoms. If that is the case, it 
would be prudent to err on the side of including those subclinical cases. The balance is 
that the traumatic stress reported must have been “considerable” and exist across 
symptom domains in the first place to meet even the lenient criterion. The decision 
admittedly leaves the researcher in the unenviable position of inheriting the designation 
of “diagnosed PTSD” from the research instrument. To be entirely clear, in the present 
study, the “PTSD symptoms present” group was not intended to represent individuals 
who would meet criteria for a PTSD diagnosis after thorough interview. Indeed, the high 
base rate of “PTSD symptoms present” in the study sample is evidence that the criteria 
are too lenient for use in clinical diagnosis. For use in the present research context, they 
suffice. 
Recommendations 
The present study was from the beginning intended to address a specific clinical 
need. Evaluation for mild TBI within the VHA should include symptom and performance 
validity testing both because of the often vague and nonspecific nature of mild TBI 
symptoms and because of the unique incentive structure that very nearly guarantees the 
presence of an opportunity for secondary gain. Currently in the VHA, SVT/PVTs are 
only administered during neuropsychological evaluation, which itself only occurs based 
on a secondary referral from a TBI physician or as a part of the compensation and 
pension process. Thus, there is no process for early identification of questionable 
response validity that would generate a referral to a neuropsychologist for clarification. 
Based on the present findings, we recommend the use of the Validity-10, at a cut score of 
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greater than or equal to 19, to generate a referral for neuropsychological testing 
(including SVT/PVTs) to clarify whether the response style is invalid or valid. 
Implementation of the recommendation would require the TBI physician or medical staff 
to total the Validity-10 items from the NSI, which is already completed at the TBI 
physician evaluation. It is critical, to reduce prejudicial treatment of veterans who screen 
positive for questionable response validity on the Validity-10, that all providers involved 
be properly educated such that a positive result is not equated with malingering or 
“gaming the system,” but is instead treated as an inconclusive test result referred out for 
clarificatory testing. 
The present study generated several recommendations for research as well. Based 
on an equivocal effect of reported PTSD symptoms on the false positive rate of the 
Validity-10, future studies may better characterize the effect in various ways. For 
example, using well validated psychiatric SVTs or more rigorous diagnostic procedures 
may help determine whether the symptoms that drive the effect are genuine. If the effects 
do appear to be genuine, then perhaps some honing of the SVT/PVTs used in the present 
study may be in order. It is further recommended, based on the strong performance of 
Validity-10 for detecting cognitive QV, that future validation studies distinguish between 
cognitive and psychiatric domains of response validity, so that any true effect may be 
replicated. Finally, though the initial validation of the NSI Validity-10 has now been 
replicated by independent research teams in independent samples, there is still much 
validation work left to be done. For example, prior validation studies relied either on too 
few criterion SVTs or on wholly psychiatric-domain criterion SVTs. None included 
PVTs. Though the present study represents a step forward in more comprehensively 
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validating the measure, it would be ideal to replicate and extend the findings with a 
variety of criterion measures across domains and modalities. 
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Chapter 6—Conclusion 
This dissertation presented a cross-validation of the Validity-10 embedded 
symptom validity indicator from the Neurobehavioral Symptom Inventory (NSI) for the 
detection of questionable response validity during evaluation for mild traumatic brain 
injury (TBI). Secondary analysis based on a multi-site, parent study estimated the test 
operating characteristics of Validity-10, using NSI results gathered during the VHA TBI 
evaluation, and using results on several other measures of symptom and performance 
validity from a clinical research battery as criteria for questionable response validity. 
Sensitivity of Validity-10 to questionable validity was moderately high (.60 - .70) to 
excellent (.90 - 1.00) at high levels of specificity (> .80). Examination of predictive value 
at different base rates of and using different criteria for questionable validity supported a 
recommendation to use a cut score of Validity-10 ≥ 19 to generate clarificatory referral to 
VHA neuropsychologists. Chi-square analyses to determine the effect of PTSD 
symptoms on the utility of Validity-10 demonstrated classification accuracy in general, 
and false positive rate in particular, is relatively poorer when used with individuals who 
reported significant PTSD symptoms. Overall, these findings support the use of Validity-
10 (at cut score Validity-10 ≥ 19) to identify those veterans being evaluation for mild TBI 
in the VA system who should be referred for comprehensive secondary evaluation by a 
clinical neuropsychologist using multiple forms of symptom and performance validity 
testing. Also recommended were further studies of the effects of PTSD symptoms on the 
accuracy of Validity-10 and studies of the differential performance for detecting 
questionable response validity in the cognitive domain. 
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Appendix 1: Cross-tabulations of criterion SVT/PVT test signs 
CVLT-II Recog (-) CVLT-II Recog (+) Totals 
LMT (-) 149 3 152 
LMT (+) 22 3 25 
   Totals 171 6 177 
CVLT-II 1-5 (-) CVLT-II 1-5 (+) Totals 
LMT (-) 143 9 152 
LMT (+) 19 6 25 
   Totals 162 15 177 
MMPI-2-RF F-r (-) MMPI-2-RF F-r (+) Totals 
LMT (-) 145 7 152 
LMT (+) 21 4 25 
   Totals 166 11 177 
MMPI-2-RF FBS (-) MMPI-2-RF FBS (+) Totals 
LMT (-) 150 2 152 
LMT (+) 23 2 25 
   Totals 173 4 177 
MMPI-2-RF Fp-r (-) MMPI-2-RF Fp-r (+) Totals 
LMT (-) 144 8 152 
LMT (+) 20 5 25 
   Totals 164 13 177 
MMPI-2-RF Fs-r (-) MMPI-2-RF Fs-r (+) Totals 
LMT (-) 144 8 152 
LMT (+) 20 5 25 
   Totals 164 13 177 
M-FAST (-) M-FAST (+) Totals 
LMT (-) 131 21 152 
LMT (+) 15 10 25 
   Totals 146 31 177 
CVLT-II 1-5 (-) CVLT-II 1-5 (+) Totals 
CVLT-II Recog (-) 143 9 152 
CVLT-II Recog (+) 19 6 25 
   Totals 162 15 177 
MMPI-2-RF F-r (-) MMPI-2-RF F-r (+) Totals 
CVLT-II Recog (-) 145 7 152 
CVLT-II Recog (+) 21 4 25 
   Totals 166 11 177 
MMPI-2-RF FBS (-) MMPI-2-RF FBS (+) Totals 
CVLT-II Recog (-) 150 2 152 
CVLT-II Recog (+) 23 2 25 
   Totals 173 4 177 
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MMPI-2-RF Fp-r (-) MMPI-2-RF Fp-r (+) Totals 
CVLT-II Recog (-) 144 8 152 
CVLT-II Recog (+) 20 5 25 
   Totals 164 13 177 
MMPI-2-RF Fs-r (-) MMPI-2-RF Fs-r (+) Totals 
CVLT-II Recog (-) 162 9 171 
CVLT-II Recog (+) 2 4 6 
   Totals 164 13 177 
M-FAST (-) M-FAST (+) Totals 
CVLT-II Recog (-) 131 21 152 
CVLT-II Recog (+) 15 10 25 
   Totals 146 31 177 
MMPI-2-RF F-r (-) MMPI-2-RF F-r (+) Totals 
CVLT-II 1-5 (-) 152 10 162 
CVLT-II 1-5 (+) 14 1 15 
   Totals 166 11 177 
MMPI-2-RF FBS (-) MMPI-2-RF FBS (+) Totals 
CVLT-II 1-5 (-) 159 3 162 
CVLT-II 1-5 (+) 14 1 15 
   Totals 173 4 177 
MMPI-2-RF Fp-r (-) MMPI-2-RF Fp-r (+) Totals 
CVLT-II 1-5 (-) 150 12 162 
CVLT-II 1-5 (+) 14 1 15 
   Totals 164 13 177 
MMPI-2-RF Fs-r (-) MMPI-2-RF Fs-r (+) Totals 
CVLT-II 1-5 (-) 153 9 162 
CVLT-II 1-5 (+) 11 4 15 
   Totals 164 13 177 
M-FAST (-) M-FAST (+) Totals 
CVLT-II 1-5 (-) 138 24 162 
CVLT-II 1-5 (+) 8 7 15 
   Totals 146 31 177 
MMPI-2-RF FBS (-) MMPI-2-RF FBS (+) Totals 
MMPI-2-RF F-r (-) 163 3 166 
MMPI-2-RF F-r (+) 10 1 11 
   Totals 173 4 177 
MMPI-2-RF Fp-r (-) MMPI-2-RF Fp-r (+) Totals 
MMPI-2-RF F-r (-) 160 6 166 
MMPI-2-RF F-r (+) 4 7 11 
   Totals 164 13 177 
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MMPI-2-RF Fs-r (-) MMPI-2-RF Fs-r (+) Totals 
MMPI-2-RF F-r (-) 159 7 166 
MMPI-2-RF F-r (+) 5 6 11 
   Totals 164 13 177 
M-FAST (-) M-FAST (+) Totals 
MMPI-2-RF F-r (-) 141 25 166 
MMPI-2-RF F-r (+) 5 6 11 
   Totals 146 31 177 
MMPI-2-RF Fp-r (-) MMPI-2-RF Fp-r (+) Totals 
MMPI-2-RF FBS (-) 160 13 173 
MMPI-2-RF FBS (+) 4 0 4 
   Totals 164 13 177 
MMPI-2-RF Fs-r (-) MMPI-2-RF Fs-r (+) Totals 
MMPI-2-RF FBS (-) 161 12 173 
MMPI-2-RF FBS (+) 3 1 4 
   Totals 164 13 177 
M-FAST (-) M-FAST (+) Totals 
MMPI-2-RF FBS (-) 143 30 173 
MMPI-2-RF FBS (+) 3 1 4 
   Totals 146 31 177 
MMPI-2-RF Fs-r (-) MMPI-2-RF Fs-r (+) Totals 
MMPI-2-RF Fp-r (-) 159 9 164 
MMPI-2-RF Fp-r (+) 9 4 13 
   Totals 164 13 177 
M-FAST (-) M-FAST (+) Totals 
MMPI-2-RF Fp-r (-) 140 24 164 
MMPI-2-RF Fp-r (+) 6 7 13 
   Totals 146 31 177 
M-FAST (-) M-FAST (+) Totals 
MMPI-2-RF Fs-r (-) 138 26 164 
MMPI-2-RF Fs-r (+) 8 5 13 
   Totals 146 31 177 
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Appendix 2: Cross-tabulation of SVT/PVT test signs by Validity-10 test signs 
Validity-10 (-) Validity-10 (+) Totals 
LMT (-) 125 27 152 
LMT (+) 10 15 25 
   Totals 135 42 177 
Validity-10 (-) Validity-10 (+) Totals 
CVLT-II Recog (-) 134 37 171 
CVLT-II Recog (+) 1 5 6 
   Totals 135 42 177 
Validity-10 (-) Validity-10 (+) Totals 
CVLT-II 1-5 (-) 130 32 162 
CVLT-II 1-5 (+) 5 10 15 
   Totals 135 42 177 
Validity-10 (-) Validity-10 (+) Totals 
MMPI-2-RF F-r (-) 132 34 166 
MMPI-2-RF F-r (+) 3 8 11 
   Totals 135 42 177 
Validity-10 (-) Validity-10 (+) Totals 
MMPI-2-RF FBS (-) 133 40 173 
MMPI-2-RF FBS (+) 2 2 4 
   Totals 135 42 177 
Validity-10 (-) Validity-10 (+) Totals 
MMPI-2-RF Fp-r (-) 128 36 164 
MMPI-2-RF Fp-r (+) 7 6 13 
   Totals 135 42 177 
Validity-10 (-) Validity-10 (+) Totals 
MMPI-2-RF Fs-r (-) 131 33 164 
MMPI-2-RF Fs-r (+) 4 9 13 
   Totals 135 42 177 
Validity-10 (-) Validity-10 (+) Totals 
M-FAST (-) 116 30 146 
M-FAST (+) 19 12 31 
Totals 135 42 177 
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